Earlier this month, Oxford Biomedica announced the launch of its new corporate brand — OXB (OXB) — designed to reinforce what management calls “its transformation into a global pure-play cell and gene ...
Dr. Frank Mathias, Chief Executive Officer of OXB, commented: “The launch of our new brand identity reinforces OXB's significant transformation into a leading pure-play cell and gene therapy CDMO.
Oxford, UK – 18 September 2024: OXB (LSE:OXB), a quality and innovation-led cell and gene therapy CDMO, today announces the launch of its new corporate brand. Oxford Biomedica is rebranding as ...
Oxford Biomedica rebrands as OXB reinforcing transformation into leading global cell and gene therapy CDMO Oxford, UK – 18 September 2024: OXB (LSE:OXB), a quality and innovation-led cell and ...
Oxford Biomedica is listed on the Aquis Stock Exchange trading with ticker code OXB.GB.PL. It has a market capitalisation of £405.57m, with approximately 105.34m shares in issue. Over the last ...